NNNN Market Analysis
News & Sentiment
37 articles · sorted by datePage 1 of 2 · 37 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio42.38
EPS (TTM)$0.132.8% YoY
Profit margin74.1%HEALTHCARE
Market cap$241.8MMicro cap
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 8.89
- P/S (TTM)
- 27.97
- EV/EBITDA
- 44.43
Profitability & growth
- ROE (TTM)
- 27.1%
- Operating margin
- 59.1%
- Revenue growth YoY
- 73.9%
- Dividend yield
- —
- Beta
- —
Last earnings
Dec 30, 2025 · Estimate $0.00 · Reported $0.09
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Anbio Biotechnology Class A Ordinary Shares
Company profileAnbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. The company is headquartered in Frankfurt am Main, Germany.
Classification
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- FRIEDRICH-EBERT-ANLAGE 35-37, FRANKFURT AM MAIN, GERMANY
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$241.8M
Shares outstanding$43.9M
52W high$44.73
52W low$5.25
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent